Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
December 01, 2021 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit
October 26, 2021 08:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program
October 25, 2021 08:30 ET
|
Akari Therapeutics Plc
Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye diseaseBuilding on early clinical data in atopic...
Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
September 22, 2021 09:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress
September 22, 2021 08:30 ET
|
Akari Therapeutics Plc
Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic...
Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium
September 10, 2021 08:30 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference
September 07, 2021 07:00 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
Akari Therapeutics Announces Private Placement
July 07, 2021 09:15 ET
|
Akari Therapeutics Plc
NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to...
Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress
June 29, 2021 16:01 ET
|
Akari Therapeutics Plc
Open Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid (BP) Phase III study of nomacopan in severe...
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
April 28, 2021 08:00 ET
|
Akari Therapeutics Plc
A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace long term steroid treatment (standard...